Lund University

Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer.

Since it launched CADscor, which could compete against molecular tests, in the second quarter, Acarix has announced clients in Germany, Denmark, and Sweden.

The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.